Age- and risk-stratified screening. Primary HPV or co-testing q5y (30–65); cytology q3y (21–29); annual in immunocompromised. Abnormal results go to ASCCP risk tables (not one-size fits all) — immediate colposcopy for HSIL/AGC/HPV 16–18+, surveillance for many ASC-US/LSIL situations.
Authored pathway active · cervical-cancer-screening.outpatient
Age- and risk-stratified screening. Primary HPV or co-testing q5y (30–65); cytology q3y (21–29); annual in immunocompromised. Abnormal results go to ASCCP risk tables (not one-size fits all) — immediate colposcopy for HSIL/AGC/HPV 16–18+, surveillance for many ASC-US/LSIL situations.
Guidelines: ACS 2020 Cervical Cancer Screening · USPSTF 2018 (updates expected) Cervical Cancer Screening · ASCCP 2019 (updated 2024) Risk-Based Management Consensus Guidelines
Phenotypes (3)
- Average Risk Routine Screening (Age 21-65)
- High Risk / Immunocompromised Screening
- Abnormal Screening Result Management
Pathway-scoped symptom and exam intake
Test this pathway's ROS and differential links
Opens the general LR starter for this pathway label.
19-panel workspace
cervical-cancer-screening · OutpatientStart patient workup
Open a scratch or linked encounter, add active problems, then keep labs, fluids, acid-base, and electrolyte tools beside the main workspace instead of losing context.
Encounter and problems
No encounter open. Add a problem to create a scratch encounter when none is open.
Multi-window tools
Unified
labs + fluids + acid-base
Labs
fast lab analyzer
Fluid
resuscitation and balance
Electrolytes
Na/K/Mg/Phos/Ca
ABG/VBG
compensation and mixed disorders
Popular entry points
6 quick-startsOr jump straight to the atlas
The Engine Atlas covers every authored disease package with setting chips and pathway badges. Open any engine to load its 19-panel workspace, backed by phenotype-aware reasoning and monitored by the Flow Assistant.